GlassScriptPhysician profile
Joseph E Casino
NPI 1922067925
$90,365.67
in general payments reported to CMS, 2019-2025
33 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $25K · 2021: $22K · 2022: $13K · 2023: $714 · 2024: $1,445 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.55 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $57,113.68 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $25,233.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,629.70 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,065.16 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $1,063.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Insmed, INC. | $745.34 | 2019-2025 | Arikayce |
| Genzyme Corporation | $465.78 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $460.95 | 2019-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $431.09 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $320.10 | 2019-2024 | Yupelri |
| Stryker Corporation | $222.40 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Takeda Pharmaceuticals U.S.A., INC. | $214.92 | 2020-2023 | Glassia |
| Grifols USA, LLC | $212.68 | 2020-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $177.66 | 2019-2023 | |
| Inari Medical, INC. | $167.91 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $98.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.95 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $75.31 | 2020-2022 | |
| Amgen INC. | $61.88 | 2025 | Tezspire |
| Electromed, INC. | $55.97 | 2019-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $51.15 | 2023-2024 | Purified Cortrophin Gel |
| Philips North America LLC | $49.91 | 2022 | |
| Genentech USA, INC. | $45.41 | 2019 | |
| Paratek Pharmaceuticals, INC. | $44.44 | 2024 | Nuzyra |
| Portola Pharmaceuticals, LLC | $32.03 | 2019 | |
| Shire North American Group INC | $31.46 | 2019 | |
| Abbvie INC. | $28.73 | 2024 | |
| Advanced Respiratory, INC | $21.01 | 2021 | |
| Verona Pharma, INC. | $18.84 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $18.16 | 2021 | |
| Viatris Specialty LLC | $16.05 | 2025 | Yupelri |
| Circassia INC. | $15.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Casino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.